GlassScriptPhysician profile
Gregory P Jones
NPI 1043357221
$3,460.47
in general payments reported to CMS, 2019-2025
33 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,849 · 2020: $304 · 2021: $110 · 2022: $300 · 2023: $269 · 2024: $248 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,359.16 | 2019-2022 | |
| Abbvie INC. | $399.84 | 2019-2023 | |
| Astellas Pharma US INC | $249.73 | 2019-2025 | Veozah |
| Becton, Dickinson and Company | $168.76 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $140.90 | 2023-2025 | Myfembree |
| Abbott Laboratories | $122.88 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Hologic Sales and Service, LLC | $121.15 | 2019-2025 | Aptima |
| Pfizer INC. | $117.31 | 2019-2023 | |
| Orexo US, INC. | $61.53 | 2019-2020 | |
| Roche Diagnostics Corporation | $60.11 | 2019-2020 | |
| Organon LLC | $46.92 | 2025 | Nexplanon |
| Sage Therapeutics, LLC | $45.52 | 2020-2024 | |
| Vertex Pharmaceuticals Incorporated | $45.10 | 2024-2025 | |
| Amag Pharmaceuticals, INC. | $44.88 | 2019 | |
| Shield Therapeutics INC | $43.94 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $41.52 | 2022 | |
| Pharmacosmos Therapeutics INC. | $40.33 | 2022-2023 | Monoferric |
| Ethicon US, LLC | $37.88 | 2020 | |
| Duchesnay USA Incorporated | $33.36 | 2019 | |
| Therapeuticsmd, INC. | $32.65 | 2019 | |
| Lupin INC. | $30.88 | 2019 | |
| Mylan Pharmaceuticals INC. | $29.06 | 2020-2022 | |
| Daiichi Sankyo INC. | $21.57 | 2021 | |
| Dexcom, INC. | $20.55 | 2023 | Dexcom G6 Transmitter |
| Mayne Pharma Commercial LLC | $20.16 | 2023 | |
| Myovant Sciences INC. | $19.94 | 2022 | |
| Agile Therapeutics, INC. | $19.57 | 2021 | |
| Minerva Surgical, INC | $17.94 | 2023 | |
| Amgen INC. | $16.16 | 2019 | |
| Meditrina | $14.01 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.86 | 2019 | |
| Asensus Surgical, INC. | $12.01 | 2019 | |
| Allergan, INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.